Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9431179 | 0.98 | F9 (1.00) | F9F10 | |
| SCHEMBL13709693 | 0.87 | F9 (0.77) | F9F10 | |
| SCHEMBL13709460 | 0.87 | F9 (0.77) | F9F10 | |
| SCHEMBL13709697 | 0.86 | F9 (0.76) | F9F10 | |
| SCHEMBL13709752 | 0.84 | F9 (0.72) | F9F10 | |
| SCHEMBL13709665 | 0.83 | F9 (1.00) | F9F10 | |
| SCHEMBL13709569 | 0.83 | F9 (0.70) | F9F10 | |
| SCHEMBL13709674 | 0.82 | F9 (0.69) | F9F10 | |
| Hydrochloric Acid SCHEMBL9432332 | 0.82 | F9 (0.71) | F9F10 | |
| Hydrochloric Acid SCHEMBL9432282 | 0.82 | F9 (0.71) | F9F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | F9 5/4885F10 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.